Aandeel Pharming Group AEX:PHARM.NL, NL0010391025

quote:

hekesoes schreef op 6 november 2017 20:48:

Bedoel hiermee PHARMINGOPTIMIST!!!!!

quote:

pharmingfan schreef op 6 november 2017 20:50:

Plasma Protease C1-inhibitor Treatment Market Is Projected To Grow From US$1.5 Bn In 2016 To US$7.9 Bn By The End Of 2025

By Anamika P -
November 6, 2017
?0

?12

?
Share on Facebook
?
Tweet on Twitter
? ?

According to estimations of the TMR report, the demand in The Global Plasma Protease C1-Inhibitor Treatment Market will expand at a strong 20.0% CAGR for the forecast period of 2017 to 2025, for the market to be evaluated at US$7.9 bn by 2025-end considerably up from its evaluated worth of US$1.5 bn in 2016. Key vendors in the plasma protease c1-inhibitor treatment market are engaged in expanding their product portfolio and expand their distribution networks in order to penetrate global markets. This has mandated vendors to meet the regulatory standards set by governing bodies at national and international level. Growing investment for innovation in inhibitor drugs, promising pipeline drugs and novel therapies, and increasing awareness for hereditary angioedema (HAE) are primarily driving the plasma protease C1-inhibitor market through 2025.

One of the key drivers of the plasma protease C1-inhibitor treatment market is the increasing usage of plasma protease C1-inhibitor treatment drugs due to the increasing incidence of acute cases of hereditary angioedema (HAE) and prophylaxis. The emergence of C1-inhibitor is considered to be a major breakthrough among several drugs introduced in the plasma protease C1-inhibitor treatment market. Berinert is a C1-esterase inhibitor for acute HAE that received approval from the European Union in 2011. Haegarda, which is derived from C1-esterase inhibitor is approved in the U.S for routine prophylaxis as a preventive measure against HAE attacks in adolescents and adults. Increasing practice of administering prophylactic treatment process for HAE patient, demand for a new route of administration of C1-inhibitor drugs, rising demand for administering drugs subcutaneously among HAE patients are some other growth drivers of the plasma protease C1-inhibitor treatment market.

Geographically, the plasma protease C1-inhibitor treatment market is divided into four key regions, namely North America, Europe, Latin America, and Rest of the World. Among these, North America stood as the leading contributor to the worldwide market for plasma protease C1-inhibitor treatment market in 2016. High prevalence of HAE in the U.S. that are actually diagnosed and treated using C1-inhibitor drugs account for the leading growth of this regional market.

The report profiles major players in the global plasma protease C1-inhibitors treatment market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major players profiled in this report include Shire plc, CSL Limited, Sanquin and Pharming Group N.V.

quote:

Madebeliefje schreef op 6 november 2017 20:54:

Lol, ik zit hier te lezen en ik vraag me af hoeveel er hier de waarheid spreken.

Wat me wel opvalt is dat ik nergens meer lees ik ga morgen bijkopen.

Ik ga het morgen eens op een afstand blijven volgen, maar pas als ik de theoretical opening price zie zal stap 1 van morgen beginnen. Ik geloof er niet in dat ook maar iemand hier weet wat morgen brengt.

En ik ben de laatste die het zal weten, aangezien ik fijn in meetings zit om 9 uur (Aaargh, what if....)

LT tunnelvisie aanhouden, best moeilijk, focussen op dat licht aan het eind van de tunnel.

quote:

voda schreef op 6 november 2017 18:19:

[...]
Hahahaha, ik zie dat nu pas. Als ik zoveel poen had, postte ik niet hier. LOL

Nee, niets in de eindveiling gekocht. (deze keer) :-)

Jullie moeten vaker die eindveiling draad van mij lezen hoor.

^___^:-)

quote:

NEVDK schreef op 6 november 2017 20:54:

[...]

Om welk uur werd dit gepubl.?

quote:

The Pigeonman schreef op 6 november 2017 20:58:

Onveranderd op 1.53$ in Amerika dus......m

quote:

E200 schreef op 6 november 2017 20:41:

Wat een dag. Het vertrouwen neemt met de dag toe. Los van de ontwikkelingen in de omzet, problemen bij de concurrentie en het vergoeden van Ruc bij meer verzekeraars draagt wat mij betreft het creëren van de financiële middelen om de pijplijn verder te ontwikkelen zwaar bij aan de huidige koersontwikkeling. Ik zit er LT in.

@Erich........casa pharming weer een stukje groter

quote:

cousin dupree schreef op 6 november 2017 18:20:

[...]

2019 Topperke, dan staan ze minstens op €10, kun je heen en trug naar Hawai ;-)

quote:

Accionista schreef op 5 november 2017 20:14:

Na Dropbox en vervolgens Google-drive (beiden overbelast door te veel downloads) heb ik een volgende dienst ingeschakeld om het geluidsbestand "Roadshow Pharming 04 Nov 2017" te verdelen.

Als de link niet wordt geblokkeerd, verloopt hij op 20-11-2017.

1drv.ms/u/s!AoCS7dO9Zck7kGQntN0OtkSayWNo

Ik volg het zeker op en bekijk al volgende mogelijkheden.

quote:

pharmingfan schreef op 6 november 2017 20:50:

Plasma Protease C1-inhibitor Treatment Market Is Projected To Grow From US$1.5 Bn In 2016 To US$7.9 Bn By The End Of 2025
By Anamika P -
November 6, 2017
According to estimations of the TMR report, the demand in The Global Plasma Protease C1-Inhibitor Treatment Market will expand at a strong 20.0% CAGR for the forecast period of 2017 to 2025, for the market to be evaluated at US$7.9 bn by 2025-end considerably up from its evaluated worth of US$1.5 bn in 2016. Key vendors in the plasma protease c1-inhibitor treatment market are engaged in expanding their product portfolio and expand their distribution networks in order to penetrate global markets. This has mandated vendors to meet the regulatory standards set by governing bodies at national and international level. Growing investment for innovation in inhibitor drugs, promising pipeline drugs and novel therapies, and increasing awareness for hereditary angioedema (HAE) are primarily driving the plasma protease C1-inhibitor market through 2025.

One of the key drivers of the plasma protease C1-inhibitor treatment market is the increasing usage of plasma protease C1-inhibitor treatment drugs due to the increasing incidence of acute cases of hereditary angioedema (HAE) and prophylaxis. The emergence of C1-inhibitor is considered to be a major breakthrough among several drugs introduced in the plasma protease C1-inhibitor treatment market. Berinert is a C1-esterase inhibitor for acute HAE that received approval from the European Union in 2011. Haegarda, which is derived from C1-esterase inhibitor is approved in the U.S for routine prophylaxis as a preventive measure against HAE attacks in adolescents and adults. Increasing practice of administering prophylactic treatment process for HAE patient, demand for a new route of administration of C1-inhibitor drugs, rising demand for administering drugs subcutaneously among HAE patients are some other growth drivers of the plasma protease C1-inhibitor treatment market.

Geographically, the plasma protease C1-inhibitor treatment market is divided into four key regions, namely North America, Europe, Latin America, and Rest of the World. Among these, North America stood as the leading contributor to the worldwide market for plasma protease C1-inhibitor treatment market in 2016. High prevalence of HAE in the U.S. that are actually diagnosed and treated using C1-inhibitor drugs account for the leading growth of this regional market.

The report profiles major players in the global plasma protease C1-inhibitors treatment market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major players profiled in this report include Shire plc, CSL Limited, Sanquin and Pharming Group N.V.

bedankt voor deze informatie:Zal dit de rede geweest zijn voor de stijging van vandaag?
Lees net dat het 20.00 geplaatst is .......dus morgen....verderrr

quote:

Madebeliefje schreef op 6 november 2017 20:54:

Lol, ik zit hier te lezen en ik vraag me af hoeveel er hier de waarheid spreken.

Wat me wel opvalt is dat ik nergens meer lees ik ga morgen bijkopen.

Ik ga het morgen eens op een afstand blijven volgen, maar pas als ik de theoretical opening price zie zal stap 1 van morgen beginnen. Ik geloof er niet in dat ook maar iemand hier weet wat morgen brengt.

En ik ben de laatste die het zal weten, aangezien ik fijn in meetings zit om 9 uur (Aaargh, what if....)

LT tunnelvisie aanhouden, best moeilijk, focussen op dat licht aan het eind van de tunnel.